- Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool

Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Ried, B., Radich, J., Anderson, G., and Hartwell, L. (2003) The case for early detection. Nature Rev. Cancer 3, 243 –252[CrossRef][Medline] Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., and Liotta, L. A. (2002) Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev. 1, 683 –695[CrossRef] Srinivas, P. R., Srivastava, S., Hannah, S., and Wright, G. L., Jr. (2001) Proteomics in early detection of cancer. Clin. Chem. 47, 1901 –1911[Abstract/Free Full Text] Marvin, L. F., Roberts, M. A., and Laurent, B. F. (2003) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin. Chim. Acta 337, 11 –21[CrossRef][Medline] Merchant, M., and Weinberger, S. R. (2000) Recent advancements in surface-enhanced laser desorption/ionization time-of-flight-mass spectrometry. Electrophoresis 21, 1164 –1167[CrossRef][Medline] Fung, E. T., and Enderwick, C. (2002) ProteinChip clinical proteomics: Computational challenges and solutions. BioTechniques 81, (Suppl. 34) 40 –41 Isaaq, H. J., Veenstra, T. D., Conrads, T. P., and Felschow, D. (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292, 587 –592[CrossRef][Medline] Isaaq, H. J., Conrads, T. P., Prieto, D. A., Tirumalai, R., and Veenstra, T. D. (2003) SELDI-TOF MS for diagnostic proteomics. Anal. Chem. 75, 149A –155A Wulfkuhle, J. D., Liotta, L. A., and Petricoin, E. F. (2003) Proteomic applications for the early detection of cancer. Nature Rev. 3, 267 –276 Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., and Liotta, L. A. (2002) Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev. Drug Discovery 1, 683 –695[CrossRef][Medline] Pusch, W., Flocco M. T., Leung, S.-M., Thiele, H., and Kostrzewa, M. (2003) Mass spectrometry-based clinical proteomics. Pharmacogenomics 4, 1 –14[CrossRef][Medline] Raj, A. J., Zhang, Z., Rosenzweig, J., Shih, L-M., Pham, T-P., Fung, E. T., Sokoll, L. J., and Chan, D. W. (2002) Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 126, 1518 –1526[Medline] Chace, D. H., Kalas, T. A., and Naylor, E. W. (2003) Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin. Chem. 49, 1797 –1817[Abstract/Free Full Text] Dooley, K. C. (2003) Tandem mass spectrometry in the clinical chemistry laboratory. Clin. Biochem. 36, 471 –481[CrossRef][Medline] Venditti, L. N., Venditti, C. P., Berry, G. T., Kaplan, P. B., Kaye, E. M., Glick, H., and Stanley, C. A. (2003) Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: A cost-effectiveness analysis. Pediatrics 112, 1005 –1015[Abstract/Free Full Text] Saugy, M., Cardis, C., Robinson, N., and Schweizer, C. (2000) Test methods: Anabolics. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 14, 111 –133[CrossRef][Medline] Aebersold, R., and Mann, M. (2003) Mass spectrometry-based proteomics. Nature 422, 198 –207[CrossRef][Medline] Menon, U., and Jacobs, I. (2002) Screening for ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 16, 469 –482[CrossRef][Medline] Finne, P., Finne, R., and Stenman, U. H. (2001) Neural network analysis of clinicopathological factors in urological disease: A critical evaluation of available techniques. Brit. J. U. Intl. 88, 825 –831 Stephan, C., Vogel, B., Cammann, H., Lein, M., Klevecka, V., Sinha, P., Kristiansen, G., Schnorr, D., Jung, K., and Leoning, S. A. (2003) An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2–20 microg/l. Urologe A. 42, 1221 –1229[CrossRef][Medline] Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. N., Hawkins, N. J., Quinn, D. I., Russell, P. J., Sutherland, R. L., Breit, S. N., Moskaluk, CA., Frierson, H. F., Jr., and Hampton, G. M. (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. U. S. A. 100, 3410 –3415[Abstract/Free Full Text] Yousef, G. M., Polymeris, M. E., Yacoub, G. M., Scorilas, A., Soosaipillai, A., Popalis, C., Fracchioli, S., Katsaros, D., and Diamandis, E. P. (2003) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 63, 2223 –2227[Abstract/Free Full Text] Makglara, A., Scorilas, A., Stephan, C., Kristiansen, G. O., Hauptmann, S., Jung, K., and Diamandis, E. P. (2000) Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56, 527 –532[CrossRef][Medline] Welsh, J. B., Sapinoso, L. M., Si, A. I., Kern, S. G., Wang-Rodriguez, J., Moskaluk, C. A., Frierson, H. F, Jr., and Hampton, G. M. (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 5974 –5978[Abstract/Free Full Text] Welsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., and Hampton, G. M. (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 98, 1176 –1181[Abstract/Free Full Text] Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., Ledbetter, J. A., Schummer, M., McIntosh, M., Drescher, C., Urban, N., and Hellstrom, K. E. (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695 –3700[Abstract/Free Full Text] Kim, J. H., Skates, S. J., Uede, T., Wong, K. k. K. K., Schorge, J. O., Feltmate, C. M., Berkowitz, R. S., Cramer, D. W., and Mok, S. C. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J. Am. Med. Assoc. 287, 1671 –1679[Abstract/Free Full Text] Diamandis, E. P., and Yousef, G. M. (2002) Human tissue kallikreins: A family of new cancer biomarkers. Clin. Chem. 48, 1198 –1205[Abstract/Free Full Text] Yousef, G. M., and Diamandis, E. P. (2001) The new human tissue kallikrein gene family: Structure, function and association to disease. Endocr. Rev. 22, 184 –204[Abstract/Free Full Text] Petricoin III, E. F., Ardekani, A. M., Hitt, B. A., Levine, P., Fusaro, V. A., Steinberg, S., Mills, G. B. Simcoe, C., Fishman, D. A., Kohn, D. C., and Liotta, L. A. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572 –575[CrossRef][Medline] Powell, K. (2003) Proteomics delivers on promise of cancer biomarkers. Nat. Med. 9, 980 Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthais, G., Burkhard, P., Hochstrasser, D. F., and Sanchez, J. C. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 3, 1486 –1494[CrossRef][Medline] Guillaume, E., Zimmerman, C., Burkhard, P. R., Hochstrasser, D. F., and Sanchez, J-C. (2003) A poteintial cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jacob disease. Proteomics 3, 1495 –1499[CrossRef][Medline] Clarke, W., Silverman, B. C., Zhang, Z., Chan, D. W., Klein, A. S., and Molmenti, E. P. (2003) Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. 237, 660 –664[CrossRef][Medline] Service, R. F. (2003) Recruiting genes, proteins for a revolution in diagnostics. Science 300, 235 –239[CrossRef] Diamandis, E. P. (2002) Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 170 Diamandis, E. P. (2003) Re: Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 95, 489 –490. Comment in J. Natl. Cancer. Inst. 2002 94, 1576–1580[Free Full Text] Burtis, C. A., and Ashwood, E. R. (1994) Tietz Textbook of Clinical Chemistry, 2nd Ed., p. 674, W. B. Saunders Co., Philadelphia Petricoin III, E. F., Ornstein, D. K., Paweletz, C. P., Ardekani, A., Hackett, P. S., Hitt, B. A., Valassco, A., Trucco, C., Wiegand, L., Wood, K., Simone, C. V., Leving, P. J., Linehan, W. M., Emmert-Buck, M. R., Steinberg, S. M., Kohn, E. C., and Liotta, L. A. (2002) Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94, 1576 –1578[Abstract/Free Full Text] Adam, B.-L., Qu, Y., Davies, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schellhammer, P. F., Yasui, Y., Feng, Z., and Wright, G. L., Jr. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609 –3614[Abstract/Free Full Text] Qu, Y., Adam, B.-L., Yasui, Y., Ward, M. D., Cazares, L. H., Schellhammer, P. F., Feng, Z., Semmes, O. J., and Wright G. L., Jr. (2002) Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminated prostate cancer from nonprostate patients. Clin. Chem. 48, 1835 –1843[Abstract/Free Full Text] Banez, L. L., Prasanna, P., Sun, L., Ali, A., Zou, Z., Adam, B. L., McLeod, D. J., Moul, J. W., and Srivastava, S. (2003) Diagnostic potential of serum proteomic patterns in prostate cancer. J. Urol. 170, 442 –446[CrossRef][Medline] Lehrer, S., Roboz, J., Ding, H., Zhao, S., Diamond, E. J., Holland, J. F., Stone, N. N., Droller, M. J., and Stock, R. G. (2003) Putative protein markers in the sera of men with prostatic neoplasms. Brit. J. U. Intl. 92, 223 –225 Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F., Luong, M. N., Luong, S. A., Reddy, S. T., and Farias-Eisner, R. (2003) Identification of biomarkers for ovarian cancer using strong anion-exchange Proteinchips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. U. S. A. 100, 12343 –12348[Abstract/Free Full Text] Service, R. F. (2003) Public projects gear up to chart the protein landscape. Science 302, 1316 –1318[Abstract/Free Full Text] Diamandis, E. P. (2003) Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin. Chem. 49, 1271 –1278 Wright, G. L., Jr., Cazares, L. H., Leung, S. N., Nasim, S., Adam, B. L., Yip, T. T., Schellhammer, P. F., Gong, L., and Vlahou, A. (1999) Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis. 2, 264 –276[CrossRef][Medline] Xiao, Z., Adam, B. L., Cazares, L. H., Clements, M. A., David, J. W., Schellhammer, P. F. Dalmasso, E. A., and Wright, G. L., Jr. (2001) Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61, 6029 –6033[Abstract/Free Full Text] Zhang, Z., Bast Jr., R. C., Fung, E. T., Yu, Y., Li, J., Rosenzweig, J., Cameron, B., Rai, A., Sokoll, L. J., Meng, X. Y., Berchuck, A., Van Haaften-Day, C., Hacker, N. F., de Bruijn, H. W. A., van der Zee, A. G. J., and Chan, D. W. (2003) A panel of three potential biomarkers discovered from serum proteomic profiling improves sensitivity of CA125 in the detection of early stage ovarian cancer—A multi-institutional study. Proc. AACR Abstract 5739 Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P., Pratomo, V., Fu, L., Hornick, N. K., Licklider, L. J., Schorge, J. O., Berkowitz, R. S., and Mok, S. C. (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9, 2904 –2911[Abstract/Free Full Text] Hlavaty, J. J., Partin, A. W., Shue, M. J., Mangold, L. A., Derby, J., Javier, T., Kelley, S., Steig, A., Briggman, J. W., Haas, G. M., and Wu, Y. J. (2003) Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 61, 1261 –1265[CrossRef][Medline] Cho, W. S. C., Yip, T. T. C., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K. C., Yip, T.-T., Lau, W.-H., Au, J. S. K., Law, S. C. K., Cheng, W.-W., Ma, V. W. S., and Lim, C. K. P. (2004) Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 10, 43 –52[Abstract/Free Full Text] Mueller, W. K., Handschumacher, R., and Wade, M. E. (1971) Serum haptoglobin in patients with ovarian malignancies. Obstet. Gynecol. 38, 427 –435[Medline] Fish, R. G., Gill, T. S., Adams, M., and Kerby, I. (1984) Serum haptoglobin and alpha-1 glycoprotein as indicators of the effectiveness of cis-diamminedichloroplatinum (CDDP) in ovarian cancer patients—A preliminary report. Eur. J. Cancer Clin. Oncol. 20, 625 –630[CrossRef][Medline] Fish, R. G., Gill, T. S., Adams, M., Faqeera, F., and Kerby, I. (1984) Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloroplatinum (CDDP) infusion therapy. Clin. Biochem. 17, 38 –41 Petricoin III, E., and Liotta, L. A. (2003) Counterpoint. The vision for a new diagnostic paradigm. Clin. Chem. 49, 1276 –1278[Free Full Text] Ghaemmaghami, S., Huh, W.-K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O’Shea, E. K., and Weissman, J. S. (2003) Global analysis of protein expression in yeast. Nature 425, 737 –741[CrossRef][Medline] Washburn, M. P., Koller, A., Oshiro, G., Ulaszek, R. R., Plouffe, D., Deciu, C., Winzeler, E., and Yates, J. R., III. (2003) Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 100, 3107 –3112[Abstract/Free Full Text] Marshall, J., Kupchak, P., Zhu, W., Yantha, J., Vrees, T., Furesz, S., Jacks, K., Smith, C., Kireeva I., Zhang, R., Takahashi M, Stanton, E., and Jackowski G. (2003) Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2, 361 –372[CrossRef][Medline] Rogers, M. A., Clarke, P., Noble, J., Munro, N. P., Paul, A., Selby, P. J., and Banks, R. E. (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization (SELDI) and neural-network analysis: Identification of key issues affecting potential clinical utility. Cancer Res. 63, 6971 –6983[Abstract/Free Full Text] Sorace, J. M., and Zhan, M. (2003) A data review and re-assessment of ovarian cancer serum proteomic profiling. B. M. C. Bioinformatics 4, 24 ( Baggerly, K. A., Morris, J. S., and Coombes, K. R. (2004) Reproducibility of SELDI-TOF protein patterns in serum: Comparing data sets from different experiments. Bioinformatics Adv Access, pp.1 –9, Oxford University Press, Oxford. Liotta, L. A., Ferrari, M., and Petricoin, E. (2003) Written in blood. Nature 425, 905[CrossRef][Medline] Diamandis, E. P. (2002) Tumor markers: Past, present and future, in Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications (Diamandis, E. P., Fritsche, H. A., Lilja, H., Chan, W. C., and Schwartz, M. K., eds) pp.3 –8, AACC Press, New York Fossel, E. T., Carr, J. M., and McDonagh, J. (1986) Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N. Eng. J. Med. 315, 1369 –1376[Abstract] Shulman, R. (1990) NMR—Another cancer-test disappointment. N. Engl. J. Med. 322, 1002 –1003. Comment in N. Engl. J. Med. 1990 322, 949–954; N. Engl. J. Med. 322, 953–958[Medline] Engan, T., Krane, J., Klepp, O., and Kvinnsland, S. (1990) Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer. N. Engl. J. Med. 322, 949 –953. Comment in N. Engl. J. Med. 322, 1002–1003[Abstract] Diamandis, E. P. (2004) Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J. Natl. Cancer Inst. 96, 353 –356[Free Full Text]

rating: 4.00 from 6 votes | updated on: 29 Jan 2007 | views: 16806 |

Rate article:

excellent! bad…